MGNX Stock Summary and Trading Ideas (Macrogenics | NASDAQ:MGNX)

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

Macrogenics trades on the NASDAQ stock market under the symbol MGNX.

As of December 18, 2025, MGNX stock price declined to $1.57 with 2,707,823 million shares trading.

MGNX has a beta of 2.54, meaning it tends to be more sensitive to market movements. MGNX has a correlation of 0.21 to the broad based SPY ETF.

MGNX has a market cap of $99.23 million. This is considered a Micro Cap stock.

Last quarter Macrogenics reported $73 million in Revenue and $.27 earnings per share. This beat revenue expectation by $44 million and exceeded earnings estimates by $.66.

In the last 3 years, MGNX traded as high as $21.88 and as low as $.99.

The top ETF exchange traded funds that MGNX belongs to (by Net Assets): VTI, VXF, IBB, VHT, IWC.

MGNX has underperformed the market in the last year with a return of -51.1%, while the SPY ETF gained +16.6%. In the last 3 month period, MGNX fell short of the market, returning -9.2%, while SPY returned +2.7%. However, in the most recent 2 weeks MGNX has outperformed the stock market by returning +13.8%, while SPY returned -1.2%.

MGNX support price is $1.54 and resistance is $1.68 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MGNX shares will trade within this expected range on the day.